Definition

References

Support resources for your patients

NEXIUM formulary database

The NEXIUM formulary database* is a simple-to-use tool that allows you to determine NEXIUM coverage for health plans specific to your area. Simply select your state and up to two health plans. Your results will show available coverage and any restrictions that may apply.

*Formulary information is provided by Fingertip Formulary^™

Select a drug to view formulary information.

Select Your State

After selecting a state, a list of health plans in your area will appear.

Select Your Health Plan

You may choose up to 2 healthcare plans. Your results will appear to the right.

Results

Print your results or change your selections.

This information is provided for general informational purposes only and is current as of June 2007. Individual plans may vary and all information is subject to change. For the most current formulary information, contact your patient's drug benefit provider.

Important Information

Approved Uses

Healing of EE
NEXIUM (esomeprazole magnesium) is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically-confirmed erosive esophagitis.

For those patients who have not healed after 4-8 weeks of treatment, an additional 4-8 week course of NEXIUM may be considered.

Maintenance of EE Healing
NEXIUM is indicated for the maintenance of healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.

Symptomatic GERD
NEXIUM is indicated for treatment of heartburn and other symptoms associated with GERD.

Pathological Hypersecretory Conditions
NEXIUM is indicated for the long-term treatment of pathological hypersecretory conditions. Dosage regimens should be adjusted to individual patient needs.

Important Safety Information
NEXIUM and NEXIUM I.V. are contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. Injection site reactions have also been reported with NEXIUM I.V.

In patients aged 12 to 17 years, the most frequently reported adverse events with NEXIUM include headache, diarrhea, abdominal pain, and nausea.

Symptomatic response to therapy does not preclude the presence of gastric malignancy.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer.

As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other proton pump inhibitors, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts, and digoxin).

Concomitant administration of esompeprazole may reduce the plasma levels of atazanavir.

NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Please see full Prescribing Information for NEXIUM.

NEXIUM News | Privacy Statement | Legal Information

NEXIUM and the color purple as applied to the capsule are registered trademarks and Purple Plus is a trademark of the AstraZeneca group of companies.
238402 5/07
Copyright © 2007 AstraZeneca LP. All rights reserved.

This product information is intended for US healthcare professionals only.
US Corporate Site

Site map Sign up for updates Contact us NEXIUM news Consumer site References

NEXIUM formulary database

The NEXIUM formulary database is a simple-to-use tool that allows you to determine NEXIUM coverage for health plans specific to your area. Simply select your state and up to two health plans. Your results will show available coverage and any restrictions that may apply.

The following definitions are generally applicable, though they may vary by plan. Please contact your patient's plan for specific information regarding his or her tier structure.

Tier 1 (Generic)
This drug is available at the lowest co-pay. Most commonly, these are generic drugs.

Tier 2 (Preferred)
This drug is available at a co-pay that is higher than the co-pay for Tier 1 drugs, but lower than the co-pay for other Tiers. Most commonly, these are brand drugs that have a formulary status of "preferred."

Tier 3 or higher (Non-preferred)
This drug is available at a higher level co-pay than Tier 1 or Tier 2 drugs. Most commonly, these are "non-preferred" brand drugs and are sometimes off of formulary.

Tiers 4, 5 and 6
Some plans have these tier levels. Drugs on these tiers are generally "non-preferred" and/or off of formulary. They also generally have higher co-pays than drugs that are on Tiers 1 or 2.

QL (Quantity Limits)
Drugs that require prior authorization. Typically, additional information must be provided to the health plan in order for these drugs to be covered.

PA (Prior Authorization)
This drug is available at a co-pay that is higher than the co-pay for Tier 1 drugs, but lower than the co-pay for other Tiers. Most commonly, these are brand drugs that have a formulary status of "preferred."

NC (Not covered)
Drugs that are not covered by the plan.

PPD (Patient pays the difference)
The plan requires that the patient pay the difference in cost between the brand product and the generic product.